2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - Hall B
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Study Population, Animal Model
PAPER

363 Drug-tolerant persister cells retain disease-initiating potential under menin inhibition

Tabea Klaus, MSc, Wallace A. Bourgeois, MD2, Meaghan Boileau, PhD3, Manoj K. Gupta4, Thomas Plenge5, George Wan6, Jan C. Schroeder7, Anjali Cremer8, Thomas Oellerich, MD9, Tina M. Schnoeder10, Florian H. Heidel IV, MD11, Scott A Armstrong, MD, PhD12, Florian Perner, MD13
1 Department of Hematology, Hemostasis, Oncology and Cell Therapy, Hannover Medical School (MHH), Hannover, Germany
2 Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
3 Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
4 Department of Hematology, Hemostasis, Oncology and Cell Therapy, Hannover Medical School (MHH), Hannover, Germany
5 Department of Hematology, Hemostasis, Oncology and Cell Therapy, Hannover Medical School (MHH), Hannover, Germany
6 Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
7 Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
8 Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
9 Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany
10 Department of Hematology, Hemostasis, Oncology and Cell Therapy, Hannover Medical School (MHH), Hannover, Germany
11 Department of Hematology, Hemostasis, Oncology and Cell Therapy, Hannover Medical School (MHH), Hannover, Germany
12 Department of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
13 Department of Hematology, Hemostasis, Oncology and Cell Therapy, Hannover Medical School (MHH), Hannover, Germany
Menin inhibitors represent the first molecularly targeted therapy for KMT2A-rearranged acute myeloid leukemia (KMT2A-r AML). Nonetheless, responses to monotherapy remain heterogeneous, and most patients ultimately relapse. In contrast to conventional cytotoxic chemotherapy or apoptosis-inducing agents, menin inhibitors function as differentiation therapies, relieving the oncogenic differentiation block rather than provoking immediate cell death. As a consequence, leukemic cells persist under sustained drug pressure for weeks to months, an extended interval that permits non-genetic adaptation and cannot be accounted for by acquired MEN1 resistance mutations alone. To define how leukemic cells endure this period and whether the cells that persist retain malignant potential, we modeled both short- and long-term responses to revumenib in vitro and in patient-derived xenograft (PDX) models, tracking the evolution of persister cell states over time.

Single-cell RNA-sequencing of 3 different KMT2A-r PDX models (KMT2A::MLLT10, KMT2A::AFF3, KMT2A::AFDN) showed that, within two weeks of treatment, a blast population diversified rapidly into distinct cellular states. Some states mirrored normal blood cell differentiation (CMP-, GMP-, and monocyte-like states). Others shared differentiation features but matched no healthy cell type while expressing hallmarks of drug-tolerant persister cells with strong enrichment of a lung-cancer derived drug-tolerant persister (DTP) signature (NES=2.17, q=0.001) and an EMT-like signature (NES=2.48, q<0.001).

Long-term persister cells isolated from mice treated with high-dose revumenib (0.3% in rodent diet) for more than 170 days were re-transplanted into secondary recipient hosts, where they initiated disease as potently as leukemic cells never exposed to the drug, with fatal leukemia developing as early as 50 days after transplantation.

Long-term treatment of OCI-AML2 (KMT2A::AFDN) cell line with 100 nM revumenib reproduced this adaptation in vitro, with a DTP signature enriched after 4–8 weeks of continuous exposure (NES=1.55, q=0.031). Mass spectrometry-based global proteome profiling linked the persister state to extracellular-matrix remodeling, with higher levels of proteins such as VIM, MMP9, ZEB2, and TGFB1. ATAC-seq revealed that AP-1 transcription factor motifs appeared selectively enriched in chromatin that opened in persister cells. ChIP-seq confirmed AP-1 binding at these newly accessible sites. Blocking AP-1 with a dominant-negative construct (A-FOS) selectively impaired the growth of persisting cells under revumenib exposure (5.85-fold fitness disadvantage by day 36; P=0.001), pointing towards AP-1 as a driver of persister-state maintenance.

Together, these results suggest that menin inhibition rapidly splits the leukemic bulk into a spectrum of differentiating persister cells that resemble maturing myeloid cells, yet a subset retains the capacity to reinitiate disease and sustains a residual KMT2A-r gene-expression program. This obscures the diagnostic boundary between a terminally differentiated cell and one still competent to reinitiate leukemia and underscores that immunophenotypic or morphologic maturation cannot be equated with eradication of the malignant clone. Translating the differentiation response to menin inhibition into durable remission will therefore require defining the molecular determinants that separate reversible persistence from bona fide terminal differentiation and preempting adaptation – either by accelerating disease eradication through doublet or triplet combinations, or by targeting persister-sustaining dependencies such as AP-1.
Tabea Klaus, MSc: No relevant conflicts of interest to declare.